Corporate reputation in the age of GLP-1 episode artwork

EPISODE · Jun 5, 2025 · 35 MIN

Corporate reputation in the age of GLP-1

from Ipsos in the UK Podcast · host Ipsos in the UK

Listen to Thomas Fife-Schaw and Nick Gabery Adams, former VP of Corporate Brand at Novo Nordisk, discuss how GLP-1 medications like Ozempic and Wegovy are changing the pharmaceutical landscape. From reshaping corporate reputation, to boosting investor confidence, discover how these drugs are rewriting the rules for pharma brands.

Listen to Thomas Fife-Schaw and Nick Gabery Adams, former VP of Corporate Brand at Novo Nordisk, discuss how GLP-1 medications like Ozempic and Wegovy are changing the pharmaceutical landscape. From reshaping corporate reputation, to boosting investor confidence, discover how these drugs are rewriting the rules for pharma brands.

NOW PLAYING

Corporate reputation in the age of GLP-1

0:00 35:33

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Ipsos in the UK Podcast?

This episode is 35 minutes long.

When was this Ipsos in the UK Podcast episode published?

This episode was published on June 5, 2025.

What is this episode about?

Listen to Thomas Fife-Schaw and Nick Gabery Adams, former VP of Corporate Brand at Novo Nordisk, discuss how GLP-1 medications like Ozempic and Wegovy are changing the pharmaceutical landscape. From reshaping corporate reputation, to boosting...

Can I download this Ipsos in the UK Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!